Pain Therapeutics, Inc. (NASDAQ:PTIE)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $1.48. Pain Therapeutics shares last traded at $1.40, with a volume of 1,386,754 shares.
The business has a 50-day moving average of $1.36.
An institutional investor recently raised its position in Pain Therapeutics stock. Geode Capital Management LLC boosted its position in shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) by 75.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 66,068 shares of the biopharmaceutical company’s stock after purchasing an additional 28,314 shares during the period. Geode Capital Management LLC owned 0.38% of Pain Therapeutics worth $56,000 at the end of the most recent reporting period. 17.40% of the stock is owned by institutional investors and hedge funds.
Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.
Recommended Story: Total Return
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.